National Cancer Institute (nci)

This study tests a vaccine called SurVaxM in 80 current or former heavy smokers at high risk for lung cancer. The vaccine trains the immune system to attack cells that make a protein called survivin, which is common in early cancer cells. The goal is to see if the vaccine can tri…

This early-phase trial tests a new two-drug combination for people whose glioblastoma (a severe brain cancer) has returned after initial treatment. The study combines a radioactive antibody that seeks out cancer cells with an immunotherapy drug that helps the immune system fight …

This study compares a new two-drug combination (teclistamab and pomalidomide) to a standard three-drug regimen for adults whose multiple myeloma has returned after initial treatment. The goal is to see if the new combo is safer and better at wiping out cancer cells to undetectabl…

This early-stage study tests the safety and best dose of the drug glofitamab when given with standard chemotherapy for people with untreated mantle cell lymphoma, a rare blood cancer. About 16 adults aged 18 to 75 with advanced disease will participate. The goal is to see if addi…

This study tests whether adding tirzepatide (a weight-loss injection) to a levonorgestrel IUD (Mirena) can eliminate precancerous cells or early-stage endometrial cancer in overweight or obese women. About 55 women will receive both treatments for 26 weeks. The goal is to avoid h…

This study tests whether giving a second type of CAR T-cell therapy (targeting CD22) can prevent relapse in people with B-cell acute lymphoblastic leukemia who had no signs of cancer after their first CAR T-cell treatment (targeting CD19). About 20 participants aged 3 to 65 will …

This study tests whether a newer targeted drug (venetoclax) works as well or better than an older targeted drug (gemtuzumab ozogamicin) when both are added to standard chemotherapy for a specific type of acute myeloid leukemia called core binding factor AML. About 162 younger adu…

This study tests a stem cell transplant approach for people whose blood cancer is caused by an inherited RUNX1 gene mutation. Researchers will adjust chemotherapy and supportive care doses for each patient to see if this improves survival compared to past results. About 98 partic…

This study tests whether adding the drug venetoclax to standard chemotherapy and a stem cell transplant can help keep acute myeloid leukemia (AML) from coming back. About 244 adults with AML in first remission will receive either venetoclax or a placebo before and after their tra…

This early-phase study tests a new treatment for people with extensive-stage small cell lung cancer or similar neuroendocrine cancers that did not respond to or came back after standard therapy. The treatment uses the patient's own immune cells (T cells) that are modified in a la…

This study tests whether a combination of hormone therapy and a targeted drug (ribociclib) works as well as chemotherapy followed by the same hormone therapy and ribociclib for people with high-stage but low-risk breast cancer. About 1,978 postmenopausal women and men with estrog…

This study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, is as effective as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy…

This study tests whether two immunotherapy drugs, botensilimab and balstilimab, can clear tiny amounts of cancer DNA from the blood of people with stage II or III colorectal cancer after standard treatment. About 20 adults whose blood still shows signs of cancer will receive the …

This study tests whether the immunotherapy drug atezolizumab can prevent stage I non-small cell lung cancer from returning after it has been completely removed by surgery. About 336 people who have had surgery for early-stage lung cancer will either receive atezolizumab or be wat…

This early-stage trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has returned or not responded to prior therapy. Teclistamab is a special antibody that helps the immune system recognize and attack cancer cells. The study aims to find the safest…

This study tests whether adding the antifungal drug itraconazole to standard heat ablation therapy can better prevent esophageal cancer in people with high-risk Barrett's esophagus. About 64 adults with precancerous changes in their esophagus will receive either itraconazole or a…

This study tests a wearable patch called TempTraq that continuously monitors body temperature in cancer patients receiving immunotherapy. The goal is to see if catching fevers early can reduce the risk of severe cytokine release syndrome (CRS), a serious immune reaction. About 13…